An incremental effectiveness analysis of lorlatinib for the treatment of ALK-positive advanced non-small cell lung cancer that has progressed after another ALK tyrosine kinase inhibitor in Portugal

Authors:

Guerreiro R, Paquete A, Iadeluca L, Almond C, Albuquerque de Almeida F, Inês M, Costa J, Borges M and Silva Miguel L

Publication type:

Conference Proceedings – Poster

Publication Name:

Virtual ISPOR Europe 2020

Citation:

Guerreiro R, Paquete A, Iadeluca L, Almond C, Albuquerque de Almeida F, Inês M, Costa J, Borges M and Silva Miguel L. An incremental effectiveness analysis of lorlatinib for the treatment of ALK-positive advanced non-small cell lung cancer that has progressed after another ALK tyrosine kinase inhibitor in Portugal. Virtual ISPOR Europe 2020. 16-19 November 2020. Poster PCN140.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies